Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from BioMarin Pharmaceuticals’s reported figures.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
FAQ
- What is BioMarin Pharmaceuticals's EBIT?
- BioMarin Pharmaceuticals (BMRN) reported EBIT of $110.92M in Q2 2026.
- How has BioMarin Pharmaceuticals's EBIT changed year-over-year?
- BioMarin Pharmaceuticals's EBIT decreased by 59.9% year-over-year, from $276.89M to $110.92M.
- What is the long-term trend for BioMarin Pharmaceuticals's EBIT?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's EBIT has grown at a 53.5% compound annual growth rate (CAGR), from -$82.34M to $456.87M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about BioMarin Pharmaceuticals's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude